Literature DB >> 722083

Rat mast cell-eosinophil interaction in antibody-dependent eosinophil cytotoxicity to Schistosoma mansoni schistosomula.

M Capron, J Rousseaux, C Mazingue, H Bazin, A Capron.   

Abstract

The involvement of IgG2a antibodies and mast cells in antibody-dependent eosinophil cytotoxicity suggested a possible interaction between mast cells and eosinophils for in vitro killing of Schistosoma mansoni schistosomula. Cell purification procedures showed that a minimum ratio of mast cells was required to obtain eosinophil cytotoxicity. The incubation of mast cells with heat-aggregated IgG2a immunoglobulins before addition to a mast cell-depleted eosinophil population induced a significant degree of inhibition of cytotoxicity, Similarly, the heat-aggregated IgG2a Fc fragment had a strong inhibitory effect whereas incubation of mast cells with Fab fragment failed to inhibit the cytotoxic effect. The Fc portion of IgG2a immunoglobulins therefore seemed to be involved in binding to the mast cell surface. Furthermore, it was demonstrated that soluble mediators released after mast cell activation either by compound 48/80, or by IgE, or IgG2a-dependent reaction had the same effect as intact mast cells. These observations suggest that the eosinophil-dependent cytotoxicity mechanism requires a signal provided by soluble mast cell mediators in addition to antibody.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 722083

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Tryptase and chymase, markers of distinct types of human mast cells.

Authors:  S S Craig; L B Schwartz
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Interferons differentially regulate histamine and TNF-alpha in rat intestinal mucosal mast cells.

Authors:  E Y Bissonnette; B Chin; A D Befus
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

3.  The effects of eosinophil activating factor on IgG-dependent sulphidopeptide leukotriene generation by human eosinophils.

Authors:  P Fitzharris; R Moqbel; K J Thorne; B A Richardson; A Hartnell; O Cromwell; A E Butterworth; A B Kay
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

Review 4.  Eosinophils as effector cells in immunity and hypersensitivity disorders.

Authors:  A B Kay
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

5.  Surface proteins of the human eosinophil. II. Effects of Schistosoma mansoni larvae on eosinophil surface proteins.

Authors:  K J Thorne; B A Richardson; A E Butterworth
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

6.  Maturation in vivo of Schistosoma mansoni schistosomula after culture in vitro with granulocytes and antibody.

Authors:  A Dessein; A E Butterworth; M A Vadas; J R David
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

7.  Presence of tumour necrosis factor or a related factor in human basophil/mast cells.

Authors:  M Steffen; M Abboud; G K Potter; Y P Yung; M A Moore
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

8.  Vesicular uptake of eosinophil peroxidase by guinea pig basophils and by cloned mouse mast cells and granule-containing lymphoid cells.

Authors:  A M Dvorak; S J Klebanoff; W R Henderson; R A Monahan; K Pyne; S J Galli
Journal:  Am J Pathol       Date:  1985-03       Impact factor: 4.307

9.  Mast cell growth on fibroblast monolayers: two-cell entities.

Authors:  H Ginsburg; D Ben-Shahar; E Ben-David
Journal:  Immunology       Date:  1982-02       Impact factor: 7.397

10.  Immunoglobulin E (IgE) responses to paramyosin predict resistance to reinfection with Schistosoma japonicum and are attenuated by IgG4.

Authors:  Mario Jiz; Jennifer F Friedman; Tjalling Leenstra; Blanca Jarilla; Archie Pablo; Gretchen Langdon; Sunthorn Pond-Tor; Hai-Wei Wu; Daria Manalo; Remigio Olveda; Luz Acosta; Jonathan D Kurtis
Journal:  Infect Immun       Date:  2009-03-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.